drugset / Trial / NCT03149029
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Phase 2
Active not recruiting
16 enrolled
Massachusetts General Hospital
Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: * Pembrolizumab (Keytruda) * Trametinib (Mekinist) * Dabrafenib (Tafinlar)
Timeline
- Start
- 2017-11-27
- Primary completion
- 2021-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Trametinib | Small molecule | — | Oral |